Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus RENORMAX.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
Intravenous: 0.5-2 mL/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 mL/kg (1850 mg iodine/kg) within a 24-hour period.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent